Barclays’s Indaptus Therapeutics INDP Stock Holding History

Barclays’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$31.6K	Buy	+13,723	New	+$29.3K	﹤0.01%	4675
2019 Q4	–	Hold	0	–	–	–	6558
2019 Q3	–	Sell	-5	Closed	-$14.9K	–	6898
2019 Q2	$49K	Buy	+5	New	+$63.1K	﹤0.01%	6103

Other funds holding INDP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's INDP Position: Q3 2026 in Review

Barclays opened a new position in Indaptus Therapeutics (INDP) in Q3 2026: 13,723 shares worth $31.6K. The stake represents ﹤0.01% of the portfolio and ranks #4675 among its holdings. This is a return to the name: Barclays previously reported a position in INDP as recently as Q2 2019.

Barclays first reported a position in INDP in Q2 2019 and has held it in 2 quarters since. The position peaked at $49K in Q2 2019. 5 funds tracked by Wall St. Rank hold INDP as of Q3 2026.

Barclays held 13,723 shares of Indaptus Therapeutics worth $31.6K as of Q3 2026.
Indaptus Therapeutics was a new Barclays position in Q3 2026.
Indaptus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4675 holding.
Barclays first reported a position in Indaptus Therapeutics in Q2 2019 and has held it in 2 quarters since.
Barclays's Indaptus Therapeutics position peaked at $49K in Q2 2019.
5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.